Emerald Bioscience Announces Ophthalmology Scientific Advisory Board Members
April 22, 2019 07:30 ET
|
Emerald Bioscience, Inc.
Long Beach, CA, April 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
Emerald Bioscience to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
April 08, 2019 08:30 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, April 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act
April 01, 2019 07:30 ET
|
Emerald Bioscience, Inc.
LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
March 25, 2019 08:00 ET
|
Emerald Bioscience, Inc.
Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019 ...
Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
March 18, 2019 07:30 ET
|
Nemus Bioscience, Inc.
Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study NB1111 Formulation Extends Pharmaceutical Activity Time to Support Once-Daily to Twice-Daily Topical Dosing ...
Nemus Bioscience to Present at 31st Annual ROTH Conference
March 13, 2019 07:36 ET
|
Nemus Bioscience, Inc.
Long Beach, CA, March 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues
March 12, 2019 07:30 ET
|
Nemus Bioscience, Inc.
Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and Inflammation Changes in Neovascularization...
Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog
March 04, 2019 07:30 ET
|
Nemus Bioscience, Inc.
Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the Retina LONG BEACH, CA, March 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc....
Nemus Bioscience Signs Agreement with Pharmaceuticals International Inc. to Develop Dosage Formulation for Human Dosing with NB1111 for Glaucoma
February 14, 2019 07:00 ET
|
Nemus Bioscience, Inc.
Long Beach, CA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
Nemus Bioscience to Present at BIO CEO & Investor Conference
February 07, 2019 08:30 ET
|
Nemus Bioscience, Inc.
LONG BEACH, CA, Feb. 07, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...